JNJ

167.25

+1.51%↑

NVS

115.07

+1.29%↑

ABT

127.38

+0.96%↑

TMO

462.78

-1.04%↓

ISRG

483.28

+0.46%↑

JNJ

167.25

+1.51%↑

NVS

115.07

+1.29%↑

ABT

127.38

+0.96%↑

TMO

462.78

-1.04%↓

ISRG

483.28

+0.46%↑

JNJ

167.25

+1.51%↑

NVS

115.07

+1.29%↑

ABT

127.38

+0.96%↑

TMO

462.78

-1.04%↓

ISRG

483.28

+0.46%↑

JNJ

167.25

+1.51%↑

NVS

115.07

+1.29%↑

ABT

127.38

+0.96%↑

TMO

462.78

-1.04%↓

ISRG

483.28

+0.46%↑

JNJ

167.25

+1.51%↑

NVS

115.07

+1.29%↑

ABT

127.38

+0.96%↑

TMO

462.78

-1.04%↓

ISRG

483.28

+0.46%↑

Search

Novo Nordisk A-S

Slēgts

SektorsVeselības aprūpe

48.22 2.55

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

47.04

Max

49.01

Galvenie mērījumi

By Trading Economics

Ienākumi

804M

29B

Pārdošana

-7.6B

78B

P/E

Sektora vidējais

18.649

40.048

EPS

6.53

Dividenžu ienesīgums

2.34

Peļņas marža

37.182

Darbinieki

77,406

EBITDA

5.9B

46B

Rekomendācijas

By TipRanks

Rekomendācijas

Pirkt

Prognoze 12 mēnešiem

+55.09% upside

Dividendes

By Dow Jones

Dividenžu ienesīgums

Sektora vidējais

2.34%

2.45%

Tirgus statistika

By TradingEconomics

Tirgus kapitalizācija

50B

316B

Iepriekšējā atvēršanas cena

45.67

Iepriekšējā slēgšanas cena

48.22

Tehniskais rādītājs

By Trading Central

Pārliecība

Weak Bearish Evidence

Novo Nordisk A-S Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2025. g. 29. jūl. 12:41 UTC

Peļņas

Novo Nordisk Shares Plummet on Guidance Cut as Wegovy Knockoffs Hurt Sales -- 2nd Update

2025. g. 29. jūl. 11:36 UTC

Peļņas

Novo Nordisk Cuts Guidance as Copycat Versions of Wegovy Hurt Results

2025. g. 1. aug. 11:10 UTC

Karstas akcijas

Global Stocks to Watch: Novo Nordisk, AXA, Daimler Truck -- WSJ

2025. g. 30. jūl. 11:10 UTC

Tirgus saruna
Peļņas

Novo Nordisk Suffering From Self-Inflicted Wounds -- Market Talk

2025. g. 30. jūl. 10:57 UTC

Tirgus saruna

Novo Nordisk's New CEO Might Need to Change U.S. Strategy -- Market Talk

2025. g. 30. jūl. 10:48 UTC

Tirgus saruna
Peļņas

Novo Nordisk's New CEO Faces Issues With No Easy Fix -- Market Talk

2025. g. 30. jūl. 10:42 UTC

Peļņas
Iegādes, apvienošanās, pārņemšana

Stock Markets Beware Summer Scares. What -2-

2025. g. 30. jūl. 10:42 UTC

Peļņas
Iegādes, apvienošanās, pārņemšana

Stock Markets Beware Summer Scares. What Microsoft Must Learn From Novo's $75 Billion Crash. -- Barrons.com

2025. g. 30. jūl. 10:38 UTC

Tirgus saruna

Novo Nordisk Could Struggle to Regain Investors' Trust -- Market Talk

2025. g. 30. jūl. 10:26 UTC

Peļņas

Global Earnings in Focus Wednesday: HSBC, UBS, Porsche, Hermès -- WSJ

2025. g. 29. jūl. 17:05 UTC

Peļņas

Novo Nordisk Shares Plummet as Competition Weighs on Sales -- 3rd Update

2025. g. 29. jūl. 16:55 UTC

Peļņas

The Obesity Bubble Has Finally Burst. Novo Nordisk Shares Drop 21%. -- Barrons.com

2025. g. 29. jūl. 13:35 UTC

Peļņas

Novo Nordisk Shares Plummet as Competition Weighs on Sales -- Update

2025. g. 29. jūl. 11:39 UTC

Peļņas

Novo Nordisk Stock Tumbles 20% After Ozempic Maker's Shock Cut to U.S. Outlook -- Barrons.com

2025. g. 29. jūl. 11:11 UTC

Peļņas

Novo Nordisk Shares Fall Over 15% After Guidance Cut

2025. g. 29. jūl. 11:09 UTC

Peļņas

Novo Nordisk: Sales Outlook Reflects Persistent Use of Compounded GLP-1s, Slower Mkt Expansion, Competition

2025. g. 29. jūl. 11:08 UTC

Peļņas

Novo Nordisk: Lowered Sales Outlook Driven by Lower Growth Views for Wegovy, Ozempic in U.S.

2025. g. 29. jūl. 11:08 UTC

Peļņas

Novo Nordisk Had Seen 2025 Sales Growth at 13%-21%, Op Profit Growth at 16%-24%

2025. g. 29. jūl. 11:07 UTC

Peļņas

Novo Nordisk Cuts 2025 Sales and Op Profit Guidance

2025. g. 29. jūl. 11:06 UTC

Peļņas

Novo Nordisk 1H Sales Increased by 18% and Operating Profit Increased by 29%

2025. g. 29. jūl. 11:06 UTC

Peļņas

Novo Nordisk Now Sees 2025 Sales Growth at 8%-14%, Op Profit Growth at 10%-16%

2025. g. 29. jūl. 11:05 UTC

Peļņas

Novo Nordisk Cuts Sales and Operating Profit Outlook for 2025

2025. g. 15. jūl. 12:38 UTC

Tirgus saruna

Novo Nordisk Faces Several Questions on Wegovy -- Market Talk

2025. g. 9. jūl. 10:59 UTC

Tirgus saruna

Pharma Companies Would Be Severely Hurt by 200% Tariff -- Market Talk

2025. g. 9. jūl. 09:17 UTC

Karstas akcijas

Stocks to Watch Wednesday: Freeport-McMoRan, Glencore, Novo Nordisk -- WSJ

2025. g. 24. jūn. 10:26 UTC

Tirgus saruna

Novo Nordisk Sends Clear Message on Copycat Drugs -- Market Talk

2025. g. 23. jūn. 13:09 UTC

Tirgus saruna

Novo Nordisk Drug Data Doesn't Change Anything -- Market Talk

2025. g. 20. jūn. 13:31 UTC

Iegādes, apvienošanās, pārņemšana

E.l.f. Beauty CEO Buys Up Smucker Stock -- Barrons.com

2025. g. 13. jūn. 11:39 UTC

Tirgus saruna

Novo Nordisk Skips to Late-Stage Development of New Obesity Drug -- Market Talk

2025. g. 13. jūn. 10:04 UTC

Tirgus saruna

Novo Nordisk Overtakes SAP to Reclaim Spot as Europe's Most Valuable Company -- Market Talk

Salīdzinājums

Cenas izmaiņa

Novo Nordisk A-S Prognoze

Cenas mērķis

By TipRanks

55.09% augšup

Prognoze 12 mēnešiem

Vidējais 73 USD  55.09%

Augstākais 90 USD

Zemākais 55 USD

Pamatojoties uz 5 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Novo Nordisk A-S — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt

5 ratings

2

Pirkt

3

Turēt

0

Pārdot

Tehniskais rādītājs

By Trading Central

62.63 / 69.23Atbalsts un pretestība

Īstermiņā

Weak Bearish Evidence

Vidējā termiņā

Bullish Evidence

Ilgtermiņā

Bearish Evidence

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

$

Par Novo Nordisk A-S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides insulin pens, growth hormone pens, and injection needles. In addition, it offers smart solutions for diabetes treatment, such as smart insulin pens and Dose Check, an insulin dose guidance application. The company has a collaboration agreement with UNICEF to tackle childhood obesity; and with Valo Health, Inc. to discover and develop novel drug programmes for cardiometabolic space. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark.